A new heparan sulfate from the mollusk Nodipecten nodosus inhibits merozoite invasion and disrupts rosetting and cytoadherence of Plasmodium falciparum

• Main Authors: Marcele F Bastos, Letusa Albrecht, Angélica M Gomes, Stefanie CP Lopes, Cristina P Vicente, Rodrigo PM de Almeida, Gustavo C Cassiano, Roberto JC Fonseca, Claudio C Werneck, Mauro SG Pavão, Fabio TM Costa
• Format: Article
• Language: English
• Published: Instituto Oswaldo Cruz, Ministério da Saúde
• Series: Memórias do Instituto Oswaldo Cruz.
• Subjects: glycosaminoglycan; severe malaria; adhesion; antimalarial; adjuvant therapy
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762019000100333&lng=en&tlng=en

BACKGROUND Despite treatment with effective antimalarial drugs, the mortality rate is still high in severe cases of the disease, highlighting the need to find adjunct therapies that can inhibit the adhesion of Plasmodium falciparum-infected erythrocytes (Pf-iEs). OBJECTIVES In this context, we evaluated a new heparan sulfate (HS) from Nodipecten nodosus for antimalarial activity and inhibition of P. falciparum cytoadhesion and rosetting. METHODS Parasite inhibition was measured by SYBR green using a cytometer. HS was assessed in rosetting and cytoadhesion assays under static and flow conditions using Chinese hamster ovary (CHO) and human lymphatic endothelial cell (HLEC) cells expressing intercellular adhesion molecule-1 (ICAM1) and chondroitin sulfate A (CSA), respectively. FINDINGS This HS inhibited merozoite invasion similar to heparin. Moreover, mollusk HS decreased cytoadherence of P. falciparum to CSA and ICAM-1 on the surface of endothelial cells under static and flow conditions. In addition, this glycan efficiently disrupted rosettes. CONCLUSIONS These findings support a potential use for mollusk HS as adjunct therapy for severe malaria.